HSTOQ — Histogen Share News
0.000.00%
Last trade - 00:00FinancialsHighly SpeculativeMicro Cap
- $0.01m
- -$5.60m
- $3.77m
Histogen: Rises on COVID-19 treatment development deal with Amerimmune
Brief: Histogen And Amerimmune Enter Into A Collaborative Development And Commercialization Agreement For Emricasan In The Treatment Of Covid-19
U.S. STOCKS ON THE MOVE-TC PipeLines, energy stocks, big banks, Plug Power
U.S. STOCKS ON THE MOVE-GreenPro Capital, Cytokinetics, Nam Tai, MyoKardia, Livent
U.S. STOCKS ON THE MOVE-Cinemark Holdings, Eidos Therapeutics, DraftKings, AMC Entertainment
Histogen: Up on completing dosing for early-stage study of male baldness therapy
Brief: Histogen Announces Completion Of Final Dosing Timepoint Milestone In Its 1B/2A Trial For Androgenic Alopecia In Men
Brief: Histogen Says Update For Its Hst-002 Dermal Filler Program
Brief: Histogen Announces Completion Of Dosing Milestone In 1B/2A Trial For Androgenic Alopecia In Men
Brief: Histogen Inc Files Prospectus For $125 Million Mixed Shelf
Brief: Histogen Reports Second Quarter 2020 Earnings And Provides Business Update
Brief: Histogen Inc. Announces Common Stock Purchase Agreement For Up To $10 Million With Lincoln Park Capital Fund, Llc
Brief: Histogen Says First Patient Dosed In Phase 1B/2A Trial Of HSt 001 For Androgenic Alopecia
Brief: Histogen Appoints Susan A. Knudson As Chief Financial Officer
Brief: Conatus Pharma - Institutional Shareholder Services, Glass Lewisrecommend Co's Shareholders Vote In Favor Of Merger With Histogen
Conatus: Up as FDA approves Histogen application to study hair loss therapy
Brief: Histogen Receives Us FDA Ind Approval To Initiate Phase 1B/2A Trial Of Hst 001 In Androgenic Alopecia
Brief: Conatus Pharmaceuticals Reports First Quarter 2020 Financial Results
Conatus rises on Histogen's application for facial wrinkles treatment